People · Operator

David Skibinski

Named in public records as an officer, director or promoter · active 2013–2023 · Other Technology, Pharmaceuticals, Other

3
Companies
10
Filings
$21.3M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
SnapMD, Inc.Other TechnologySeries A$18.7M$197.6M2013
NemusPharmaceuticalsSeed$1.9M$17.3M2014
FiberX Inc.OtherPre-Seed$621K$2.6M2023
Operator network

David Skibinski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

David Lam · 3 companies · 1 sharedDavid LamDoug Campbell · 3 companies · 1 sharedDoug CampbellDouglas Campbell · 3 companies · 1 sharedDouglas CampbellDavid T. Lam · 1 companies · 1 sharedDavid T. LamGeorge Tierney · 1 companies · 1 sharedGeorge TierneyRichard P. Boutin · 1 companies · 1 sharedRichard P. BoutinBrian Murphy · 15 companies · 1 sharedBrian MurphyJohn Hollister · 2 companies · 1 sharedJohn HollisterCosmas Lykos · 1 companies · 1 sharedCosmas LykosElizabeth Berecz · 1 companies · 1 sharedElizabeth BereczJerry McLaughlin · 1 companies · 1 sharedJerry McLaughlinReg Lapham · 1 companies · 1 sharedReg LaphamWade Lang · 1 companies · 1 sharedWade LangSnapMD, Inc. · $18.7M raisedSnapMD, Inc.Nemus · $1.9M raisedNemusFiberX Inc. · $0.6M raisedFiberX Inc.David SkibinskiDS
David Skibinski Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside David Skibinski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Brian Murphy115
Doug Campbell13
David Lam13
Douglas Campbell13
John Hollister12
Jerry McLaughlin11
Wade Lang11
Richard P. Boutin11
David T. Lam11
George Tierney11
Elizabeth Berecz11
Cosmas Lykos11
Reg Lapham11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.